Usage of biologic and biosimilar products      

FOI REFERENCE: 24348   FOI DATE: 6^th September 2024     

Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

• Abatacept [Orencia]                            13
• Adalimumab [Humira]                         28
• Adalimumab Biosimilars                     504
• Apremilast [Otezla]                             0
• Baricitinib [Olumiant]                          *
• Bimekizumab [Bimzelx]                      0
• Certolizumab [Cimzia]                        28
• Etanercept [Enbrel]                             9
• Etanercept Biosimilars                        169
• Filgotinib [Jyseleca]                            10
• Golimumab [Simponi]                         15
• Guselkumab [Tremfya]                       0
• Infliximab [Remicade]                         0
• Infliximab Biosimilars                          38
• Ixekizumab [Taltz]                               0
• Risankizumab [Skyrizi]                        0
• Rituximab [MabThera]                         *
• Rituximab Biosimilars                         42
• Sarilumab [Kevzara]                           5
• Secukinumab [Cosentyx]                   42
• Tocilizumab [Ro Actemra]                  58
• Tocilizumab Biosimilars                      38
• Tofacitinib [Xeljanz]                            9
• Upadacitinib [Rinvoq]                         9
• Ustekinumab [Stelara]                        *
• Ustekinumab Biosimilar                      0

*This relates to low numbers between 1 and 5. Under section 40 (ii) of the Freedom of Information Act 2000, statistically low numbers that potentially identify personal data are required to be withheld because of the Trusts obligation to protect personal data under the Data Protection Act 2018